Artículo original
Vol. 46 Núm. 3 (2026)
22 min
SABRINA1, Evy DAMAYANTHI1, Mira DEWI2, Ekowati HANDHARYANI3
1 Department of Community Nutrition, Faculty of Medicine and Nutrition, IPB University, Bogor, Indonesia.
2 Medical Study Program, Faculty of Medicine and Nutrition, IPB University, Bogor, Indonesia.
3 Department of Clinic, Reproduction, and Pathology, School of Veterinary Medicine and Biomedical Science, IPB University, Bogor, Indonesia.
Cómo citar
Métricas
199
Visualizaciones
21
Descargas
Compartir
Compartir
Resumen (EN)
Obesity is associated with visceral fat accumulation, dyslipidemia, and chronic low-grade inflammation. Kefir and Moringa oleifera have been proposed as potential anti-obesity and anti-inflammatory agents through various metabolic and immunological mechanisms. However, the available preclinical evidence remains scattered and has not been systematically synthesized.
Objective: This systematic review aimed to summarize the available evidence regarding the effects of kefir and Moringa oleifera on obesity- and inflammation-related parameters in experimental animal models.
Methods: A systematic literature search was conducted following the PRISMA guidelines using PubMed as the primary bibliographic database, with supplementary searches of studies published through the MDPI and Nature publishing platforms. Of the 93 records identified, 11 studies met the eligibility criteria and were included in the qualitative synthesis, comprising five studies on kefir and six on Moringa oleifera.
Results: Most included studies reported that kefir supplementation was associated with reductions in body weight, improvements in lipid profiles, and decreases in inflammatory biomarkers, including TNF-α and IL-6. Moringa oleifera demonstrated similar beneficial effects through antioxidant activity, regulation of metabolic-related genes, and attenuation of inflammatory responses. Nevertheless, substantial heterogeneity was observed regarding animal models, intervention types, dosages, treatment duration, and outcome measures.
Conclusions: Current preclinical evidence suggests that kefir and Moringa oleifera individually have promising anti-obesity and anti-inflammatory properties. However, no included study directly evaluated their combined administration. Therefore, any potential synergistic effect should be considered a biologically plausible hypothesis that warrants further investigation rather than a conclusion supported by direct evidence.
Palabras clave (EN):
Introduction
Obesity is one of the global health problems that continues to increase and contributes to various non-communicable diseases (NCDs), including diabetes and hypertension. The prevalence of obesity has consistently increased in many countries, particularly in urban areas experiencing changes in dietary patterns and lifestyles. In Indonesia, the results of the Indonesian Health Survey (SKI) 2023 showed that the prevalence of obesity among the adult population (>18 years) reached 23.4%, an increase compared to the 2018 Basic Health Research (Riskesdas) data of 21.8%1,2. Several factors accelerating this increase include high consumption of sugar- rich and processed foods, low levels of physical activity, and socioeconomic conditions3.
Obesity is characterized by excessive accumulation of body fat, particularly in the visceral area, which plays an important role in the development of metabolic and cardiovascular disorders. Increased visceral fat has been shown to be a strong predictor of prediabetes, with a prevalence ratio of 2.18, thereby increasing the risk of developing type 2 diabetes mellitus4. Dysfunctional visceral fat produces various inflammatory mediators that trigger systemic inflammation and increase the risk of NCDs. Elevated levels of cytokines such as IL-6 and TNF-α in obesity have been associated with a high risk of cardiovascular disease5.
Low-grade chronic inflammation accompanying obesity is largely influenced by the activity of adipokines released by adipose tissue, including TNF-α and IL-6, which subsequently affect lipid metabolism6. Increased visceral fat is also associated with dyslipidemia, characterized by elevated triglycerides and LDL and reduced HDL levels, particularly in individuals with a long duration of obesity7. Furthermore, inflammatory processes can induce significant changes in lipid profiles, including increased saturated fatty acids and VLDL, thereby exacerbating inflammatory conditions8. Lipid profiles not only reflect metabolic status but can also serve as indicators of inflammation and cardiovascular disease risk8.
Kefir is a fermented milk product produced through the symbiotic activity of lactic acid bacteria and yeasts and is recognized as a functional food due to its content of live microorganisms and bioactive components resulting from fermentation. Traditional consumption of kefir has long been associated with health benefits, particularly in supporting gastrointestinal function and modulating immune responses9. These characteristics make kefir one of the fermented foods widely developed and studied in the context of metabolic health10.
In addition to kefir, Moringa (Moringa oleifera) is a plant widely used as food and traditional medicine in many developing countries. Moringa leaves are known to be rich in bioactive compounds such as flavonoids, phenolic compounds, vitamins, and minerals, which contribute to antioxidant and anti-inflammatory activities11,12. These nutritional and phytochemical contents make Moringa leaves potentially beneficial in improving metabolic conditions associated with obesity and chronic inflammation13. Furthermore, evidence from a systematic review and meta-analysis of Indonesian medicinal plants identified Moringa oleifera as one of the most promising candidates for obesity management due to its pancreatic lipase inhibitory activity and abundance of bioactive compounds14.
Although kefir and Moringa have been widely used and reported to have potential health benefits, scientific evidence regarding their roles in obesity and metabolic inflammation remains scattered across studies with diverse designs and parameters. Therefore, a systematic review is needed to summarize and evaluate the available scientific evidence regarding the roles of kefir and Moringa leaves on obesity and inflammation parameters in animal models.
Methods
Study Design
This study was conducted as a systematic review to evaluate the anti-obesity and anti-inflammatory effects of kefir and Moringa oleifera in experimental animal models. The review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. The review protocol was pros pec tively registered in the PROSPERO database (Registra tion No. CRD420261302144). Since no eligible studies directly investigated the combined administration of kefir and Moringa oleifera, the evidence for each intervention was synthesized separately and subsequently integrated through mechanistic interpretation.
Literature Search Strategy
A comprehensive literature search was conducted between 27 and 30 May 2025. PubMed was used as the primary bibliographic database, while additional manual searches were performed through the publisher websites of MDPI and Nature Portfolio to identify potentially relevant studies that might not have been retrieved during the primary database search. The search strategy was developed based on the Population, Intervention, Comparison, and Outcome (PICO) framework.
For studies evaluating kefir, the Boolean search strategy was: (“kefir”) AND (“anti-obesity” OR “anti-inflammation”) AND (rat OR rats OR mice OR murine OR animal). For studies evaluating Moringa oleifera, the Boolean search strategy was: (“Moringa oleifera”) AND (“anti-obesity” OR “anti-inflammation”) AND (rat OR rats OR mice OR murine OR animal). No restrictions were applied regarding animal species. The reference lists of eligible articles were also screened manually to identify additional relevant studies.
Eligibility Criteria
Studies were considered eligible if they met the following inclusion criteria:
The exclusion criteria were:
Study Selection
All retrieved records were imported into the Rayyan web application to facilitate duplicate removal and study screening. After duplicate removal, titles and abstracts were screened according to the predefined eligibility criteria. Subsequently, the full texts of potentially eligible studies were assessed for inclusion. Study selection was conducted by the first author, and the eligibility of the included studies was subsequently reviewed and discussed with the co-authors before the final selection was established. The study selection process is summarized in the PRISMA flow diagram (Figure 1).
Data Extraction
Data were extracted from each included study using a standardized data extraction form. The extracted information included:
The extracted data were independently checked for consistency before descriptive synthesis.
Risk of Bias Assessment
The methodological quality of the included animal studies was assessed using the SYRCLE (Systematic Review Centre for Laboratory Animal Experimentation) Risk of Bias tool, which is specifically designed for animal intervention studies. The assessment covered ten methodological domains: sequence generation, baseline characteristics, allocation concealment, random housing, blinding of caregivers and investigators, random outcome assessment, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias. Each domain was classified as having low, high, or unclear risk of bias according to the methodological information reported in the original publications. The assessment was conducted by the first author and subsequently reviewed by the co-authors prior to interpretation of the findings.
Data Synthesis
Owing to the heterogeneity of the included studies with respect to animal models, intervention types, treatment duration, dosages, and outcome measurements, a quantitative meta-analysis was not considered appropriate. Therefore, the findings were synthesized narratively. The discussion was organized into three major themes: (1) the anti-obesity and anti- inflammatory effects of kefir, (2) the anti-obesity and anti-inflammatory effects of Moringa oleifera, and (3) the potential mechanistic integration of both interventions based on the available preclinical evidence. As no included study directly evaluated the combined administration of kefir and Moringa oleifera, the proposed synergistic effects are presented as a mechanistic hypothesis rather than direct empirical evidence.
Discussion
Effects of Kefir on Anti-Obesity and Anti-Inflammatory Parameters
The results of this systematic review indicate that kefir- based interventions, including kefir powder, kefir peptides, probiotic-enriched kefir, and kefir exopolysaccharide (KEPS), consistently exert beneficial effects on the improvement of obesity and chronic inflammation induced by a high-fat diet (HFD) in animal models. The consistency of these findings is evident across several key parameters, including reductions in body weight, visceral adipose mass, improvement of lipid profiles, and decreases in inflammatory cytokines such as TNF-α, IL-1β, IL-6, and MCP-1. The uniform pattern of improvement across studies suggests that kefir acts through interacting metabolic and immunological mechanisms, resulting in systemic effects on metabolic inflammation.
Inhibition of Lipogenesis and Enhancement of Fat Oxidation
A study by Choi et al. (2017) reported that kefir powder supplementation significantly reduced body weight, epididymal fat mass, and hepatic triglycerides in HFD-induced mice15. These effects are largely associated with the ability of kefir to suppress lipogenesis through the downregulation of lipogenic enzyme expression and to enhance fatty acid oxidation in adipose tissue. Thus, kefir directly corrects lipid metabolism disturbances that underlie the pathogenesis of obesity. In addition, the inflammatory milieu of adipose tissue was also improved, indicating that reductions in adiposity are closely linked to decreased local immunological stress.
These findings are supported by Kim et al. (2017), who investigated kefir peptides. Kefir peptides were shown to inhibit triglyceride formation in adipose tissue and the liver through the downregulation of enzymes such as fatty acid synthase (FAS). The study also demonstrated that kefir peptides reduced body weight, decreased fat deposition, and produced significant metabolic improvements16. These results confirm that the bioactive components of kefir act at the molecular level to regulate the balance between lipid anabolism and catabolism.
Reduction of Proinflammatory Cytokines and Improvement of Inflammatory Status
Low-grade chronic inflammation is a hallmark of obesity and plays an important role in insulin resistance. In the study by Kim et al. (2017), kefir peptides significantly reduced TNF-α and IL-1β levels, indicating that this intervention effectively attenuated adipose and systemic inflammation16. The reduction of these cytokines is particularly important because TNF-α and IL-1β are involved in impaired insulin signaling and pathological lipolysis.
The study by Tung et al. (2020) using an ApoE-knockout rat model, which represents a model of atherosclerosis, demonstrated that kefir peptides reduced macrophage accumulation, oxidative stress, and atherosclerotic lesion formation in HFD-fed animals17. Although the model focused on atherosclerosis, the inflammatory pathways involved overlap with those of obesity, making the findings relevant. Oxidative stress and M1 macro phage infiltration are major drivers of metabolic inflammation, and the ability of kefir to suppress both pathways highlights its strong anti-inflammatory potential.
Modulation of Gut Microbiota and Reduction of Endotoxemia
One of the most consistent mechanisms of kefir is its ability to modulate the gut microbiota. This mechanism is supported by studies on Indonesian kefir grains showing the presence of lactic acid bacteria with probiotic characteristics and cholesterol-lowering potential, highlighting the role of kefir microorganisms in metabolic regulation18. Chen et al. (2021) found that administration of AB-kefir (probiotic-enriched kefir) for 14 weeks significantly reduced MCP-1 levels and M1 macro phage infiltration in adipose tissue. Concurrently, there was an increase in beneficial bacteria and a reduction in intestinal permeability19. This improvement is important because increased intestinal permeability induced by HFD allows bacterial endotoxins (LPS) to enter the circulation, triggering systemic inflammation. By improving gut barrier integrity, kefir directly reduces metabolic endotoxemia and the low-grade inflammation underlying chronic obesity.
The reduction in M1 macrophage infiltration is particularly meaningful, as these cells are the primary source of TNF-α and IL-6 in obesity. These results demonstrate a direct link between improvements in gut microbiota and reduced adipose inflammation.
Protection of Pancreatic β Cells and Improvement of Glycemic Control
The effects of kefir are not limited to adipose tissue. Yen et al. (2025) investigated kefir exopolysaccharide (KEPS) and found that KEPS not only reduced IL-6 and TNF-α levels but also protected pancreatic β cells from oxidative stress and improved glycemic control in HFD–STZ-induced type 2 diabetic rats20. These findings indicate that kefir has pleiotropic effects, simultaneously influencing inflammatory, endocrine, and metabolic pathways. The fact that KEPS acts on β cells suggests broader potential applications in metabolic inflammatory conditions.
Based on the synthesis of all literature included in this review, kefir exerts its effects through several major biological pathways: reducing lipogenesis and enhancing fatty acid oxidation; suppressing proinflammatory cytokines (TNF-α, IL-1β, IL-6); reducing M1 macrophage infiltration and MCP-1 in adipose tissue; enhancing antioxidant activity and reducing oxidative stress; normalizing gut microbiota and improving intestinal permeability; protecting pancreatic β cells and improving glycemic control.
The integration of these findings indicates that kefir does not act on a single metabolic target but rather addresses multiple interconnected pathways involved in the pathophysiology of obesity. This positions kefir as a highly promising nutraceutical candidate, particularly for obesity accompanied by chronic inflammation commonly observed in clinical practice and preclinical research.
Effects of Moringa on Anti-Obesity and Anti-Inflammatory Parameters
Various preclinical studies indicate that Moringa oleifera has significant biological potential in improving obesity, inflammation, and metabolic parameters in animal models. These effects are attributed to its bioactive compounds, including flavonoids (quercetin and kaempferol), phenolic acids (chlorogenic acid), and isothiocyanates, which possess antioxidant and anti-inflammatory activities. Based on the studies summarized in Table 2, the mechanisms of action of Moringa oleifera include reductions in systemic inflammation, improvement of oxidative stress, modulation of visceral adiposity, and regulation of genes and proteins involved in energy metabolism.
Reduction of Proinflammatory Cytokines and Enhancement of Antioxidant Capacity
A study by Omodanisi et al. (2017) showed that administration of methanolic Moringa oleifera leaf extract to streptozotocin (STZ)-induced diabetic Wistar rats significantly reduced levels of proinflammatory cytokines TNF-α and IL-6. In addition, malondialdehyde (MDA) levels, a marker of oxidative stress, were reduced, accompanied by increased activity of antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH)21. These findings indicate that Moringa oleifera acts by improving redox balance and suppressing systemic inflammation, two processes that play critical roles in the pathogenesis of obesity and metabolic disorders.
Reduction of Visceral Adiposity and Improvement of Metabolic Parameters
In a zebrafish obesity model, Nakayama et al. (2020) reported that supplementation with Moringa oleifera leaf powder significantly reduced visceral adipose tissue (VAT), body weight, total cholesterol levels, and fasting glucose22. The reduction in VAT has important metabolic implications, as visceral adipose tissue is a major source of proinflammatory cytokines and contributes to insulin resistance. These results suggest that Moringa oleifera can improve metabolic adaptation to obesogenic diets and reduce the risk of metabolic inflammation.
Regulation of Genes and Proteins Involved in Energy Metabolism
The anti-obesity effects of Moringa oleifera are also mediated through the regulation of molecular pathways involved in energy balance. Ezzat et al. (2020) demonstrated that administration of Moringa oleifera extract to high-fat diet–fed Wistar rats increased the expression of the MC4R and PPAR-α genes23. MC4R plays a role in appetite regulation and energy balance, while PPAR-α is crucial for fatty acid oxidation and lipid metabolism. The upregulation of these genes indicates that Moringa oleifera not only reduces body weight phenotypically but also modulates energy regulation at the molecular level.
In addition, Syamsunarno et al. (2021) reported that ethanol extract of Moringa oleifera leaves in high-fat diet–fed mice reduced brown adipose tissue (BAT) weight and increased the expression of bone morphogenetic protein 7 (BMP7)24. BMP7 is known to play a role in the differentiation and function of brown adipose tissue, contributing to increased energy expenditure. These findings indicate that Moringa oleifera can influence energy metabolism through modulation of adipose tissue.
Improvement of Metabolic Syndrome Parameters
A study by López et al. (2018) in a Wistar rat model of metabolic syndrome showed that supplementation with Moringa oleifera leaf powder significantly reduced fasting glucose, triglycerides, and abdominal circumference25. These parameters are important indicators of central obesity and dyslipidemia. These results further strengthen the evidence that Moringa oleifera exerts comprehensive effects on multiple components of metabolic syndrome. These findings are consistent with previous evidence indicating that dietary interventions affecting glycemic responses play important roles in obesity and metabolic syndrome management26.
Safety Considerations and Context of Use
Although most studies report beneficial effects, Zunica et al. (2021) found that supplementation with Moringa oleifera seed extract in rats with triple-negative breast cancer undergoing chemotherapy did not improve body weight or reduce visceral fat and potentially worsened tumor outcomes27. These findings indicate that the effects of Moringa oleifera are context- dependent and may vary depending on pathological conditions and concurrent therapies.
Overall, preclinical evidence suggests that Moringa oleifera is a promising natural anti-obesity and anti-inflammatory agent that acts through multiple mechanisms, including improvements in systemic inflammation, oxidative stress, visceral adiposity, and energy metabolism regulation. However, its effects are context-dependent, and caution is warranted in certain pathological conditions, highlighting the need for further research before broader clinical application.
Mechanistic Integration of Kefir and Moringa for Obesity and Inflammation Interventions
Although no included study directly evaluated the combined administration of kefir and Moringa oleifera, the available preclinical evidence suggests that both interventions act through complementary biological pathways. Kefir primarily modulates gut microbiota, enhances gut barrier integrity, reduces circulating endotoxins, and improves lipid metabolism. In contrast, Moringa oleifera exerts anti-inflammatory and antioxidant effects through bioactive compounds such as flavonoids, isothiocyanates, and phenolic acids, which regulate inflammatory signaling pathways including NF-κB. Therefore, the following mechanistic integration should be interpreted as a biologically plausible hypothesis rather than direct experimental evidence.
Based on the available evidence, several complementary biological mechanisms may explain the potential interaction between kefir and Moringa oleifera, although these mechanisms have not yet been experimentally validated in combination studies. First, the reduction of proinflammatory cytokines, particularly TNF-α, may be enhanced through dual mechanisms: kefir reduces M1 macrophage infiltration in adipose tissue (as shown in AB-kefir studies), while Moringa directly inhibits NF-κB activation, thereby suppressing TNF-α and IL-6 production. The combination of reducing inflammatory cell sources and suppressing inflammatory molecular pathways provides an opportunity for additive or synergistic effects on metabolic inflammation.
Second, endogenous antioxidant activity may be more strongly enhanced through the combination of bioactive components. Kefir exopolysaccharide (KEPS) is known to increase antioxidant capacity and reduce oxidative stress in metabolic tissues, while Moringa flavonoids such as quercetin and kaempferol enhance the activity of antioxidant enzymes SOD, CAT, and GSH. Together, these effects may provide more optimal protection against oxidative damage that drives chronic inflammation in obesity.
Third, both kefir and Moringa influence lipid metabolism and visceral adiposity through different pathways. Kefir improves gut microbiota profiles and reduces endotoxins (LPS), thereby suppressing adipose inflammation and improving lipid metabolism, whereas Moringa activates PPAR-α, enhancing fatty acid oxidation and reducing fat storage. These mechanisms may result in greater improvements in visceral adiposity compared with either intervention alone.
Fourth, the combination of kefir and Moringa may modulate macrophage polarization through complementary mechanisms based on empirical findings summarized in Tables 2 and 3. Kefir studies consistently demonstrate reductions in macrophage infiltration and inflammatory mediators such as MCP-1, TNF-α, and IL-6 in adipose tissue, reflecting decreased activation of proinflammatory immune responses. Meanwhile, Moringa oleifera interventions have been reported to reduce the same proinflammatory cytokines and improve oxidative stress through increased antioxidant enzyme activity (SOD, CAT, and GSH). Improvements in the inflammatory and redox environment biologically support a shift in macrophage responses from a predominantly proinflammatory phenotype toward a more anti-inflammatory profile, thereby contributing to reduced metabolic inflammation in obesity.
Overall, the findings of this review indicate that kefir and Moringa oleifera individually influence multiple biological pathways involved in obesity and metabolic inflammation. Their complementary mechanisms provide a plausible biological rationale for future investigation of combined interventions. However, because no included study directly evaluated the combined administration of kefir and Moringa oleifera, any proposed synergistic effects should be regarded as a hypothesis that requires validation in well-designed experimental studies.
The overall findings should also be interpreted in light of the methodological quality of the included studies. Although the SYRCLE risk of bias assessment indicated a generally low risk of bias across several methodological domains, insufficient reporting of sequence generation, allocation concealment, random housing, and blinding procedures resulted in an unclear risk of bias in several domains. Therefore, while the available evidence supports the beneficial effects of kefir and Moringa oleifera in preclinical models, the findings should be interpreted with appropriate caution.
Strengths and Limitations
This systematic review has several important strengths. First, it integrates and synthesizes findings from multiple preclinical studies evaluating the anti-obesity and anti-inflammatory effects of kefir and Moringa oleifera. This approach provides a comprehensive overview of the biological activities and underlying mechanisms of each intervention. Further more, by integrating evidence from separate intervention studies, this review proposes a biologically plausible framework for understanding their potential complementary mechanisms, which may serve as a basis for future experimental studies investigating their combined administration.
This review also has several limitations. Variations in study design, forms of intervention (kefir, kefir peptides, Moringa powder, Moringa extracts), and treatment duration among the reviewed studies may affect the consistency of the findings. Differences in methods for measuring inflammatory biomarkers and the lack of uniformity in reported parameters may also limit direct comparability of the results. In addition, the SYRCLE risk of bias assessment indicated that several included studies lacked detailed reporting of sequence generation, allocation concealment, random housing, and blinding procedures, resulting in an unclear risk of bias in several methodological domains. These methodological limitations should be considered when interpreting the available evidence. Nevertheless, this systematic review provides a comprehensive scientific synthesis for understanding the potential of kefir and Moringa leaves as nutraceutical agents in the context of obesity and inflammation. These findings may serve as a foundation for further, more standardized research, including more in-depth mechanistic studies and investigations in animal and human models.
Conclusion
This systematic review suggests that kefir and Moringa oleifera individually exert beneficial anti-obesity and anti-inflammatory effects in preclinical animal studies. The available evidence indicates improvements in lipid metabolism, reductions in proinflammatory cytokines, and modulation of biological pathways involved in obesity and metabolic inflammation. Although no included study directly evaluated the combined administration of kefir and Moringa oleifera, their complementary mechanisms provide a biologically plausible rationale for future investigation.
These findings provide a scientific basis for the further development of functional food–based strategies targeting obesity-associated inflammation. However, additional well-designed experimental studies directly evaluating the combined administration of kefir and Moringa oleifera, followed by appropriately designed clinical studies, are needed to confirm their efficacy, safety, and potential synergistic effects.
References
Explorar
Artículos
Volúmenes
Sobre la revista
Más leídos
Nutrición Clínica y Dietética Hospitalaria
Nutrición Clínica y Dietética Hospitalaria
Nutrición Clínica y Dietética Hospitalaria
Nutrición Clínica y Dietética Hospitalaria
Nutrición Clínica y Dietética Hospitalaria